Literature DB >> 14573627

Ribonucleotide reduction in Mycobacterium tuberculosis: function and expression of genes encoding class Ib and class II ribonucleotide reductases.

Stephanie S Dawes1, Digby F Warner, Liana Tsenova, Juliano Timm, John D McKinney, Gilla Kaplan, Harvey Rubin, Valerie Mizrahi.   

Abstract

Mycobacterium tuberculosis, the causative agent of tuberculosis, possesses a class Ib ribonucleotide reductase (RNR), encoded by the nrdE and nrdF2 genes, in addition to a putative class II RNR, encoded by nrdZ. In this study we probed the relative contributions of these RNRs to the growth and persistence of M. tuberculosis. We found that targeted knockout of the nrdF2 gene could be achieved only in the presence of a complementing allele, confirming that this gene is essential under normal, in vitro growth conditions. This observation also implied that the alternate class Ib small subunit encoded by the nrdF1 gene is unable to substitute for nrdF2 and that the class II RNR, NrdZ, cannot substitute for the class Ib enzyme, NrdEF2. Conversely, a DeltanrdZ null mutant of M. tuberculosis was readily obtained by allelic exchange mutagenesis. Quantification of levels of nrdE, nrdF2, nrdF1, and nrdZ gene expression by real-time, quantitative reverse transcription-PCR with molecular beacons by using mRNA from aerobic and O(2)-limited cultures showed that nrdZ was significantly induced under microaerophilic conditions, in contrast to the other genes, whose expression was reduced by O(2) restriction. However, survival of the DeltanrdZ mutant strain was not impaired under hypoxic conditions in vitro. Moreover, the lungs of B6D2/F(1) mice infected with the DeltanrdZ mutant had bacterial loads comparable to those of lungs infected with the parental wild-type strain, which argues against the hypothesis that nrdZ plays a significant role in the virulence of M. tuberculosis in this mouse model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14573627      PMCID: PMC219568          DOI: 10.1128/IAI.71.11.6124-6131.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement.

Authors:  T Parish; N G Stoker
Journal:  Microbiology       Date:  2000-08       Impact factor: 2.777

2.  Identification of RNR4, encoding a second essential small subunit of ribonucleotide reductase in Saccharomyces cerevisiae.

Authors:  M Huang; S J Elledge
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  The evolving relation between humans and Mycobacterium tuberculosis.

Authors:  B R Bloom; P M Small
Journal:  N Engl J Med       Date:  1998-03-05       Impact factor: 91.245

4.  Antibiotic resistance gene cassettes derived from the omega interposon for use in E. coli and Streptomyces.

Authors:  M H Blondelet-Rouault; J Weiser; A Lebrihi; P Branny; J L Pernodet
Journal:  Gene       Date:  1997-05-06       Impact factor: 3.688

5.  Analysis of transcription of the Staphylococcus aureus aerobic class Ib and anaerobic class III ribonucleotide reductase genes in response to oxygen.

Authors:  M Masalha; I Borovok; R Schreiber; Y Aharonowitz; G Cohen
Journal:  J Bacteriol       Date:  2001-12       Impact factor: 3.490

6.  Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin.

Authors:  D R Sherman; M Voskuil; D Schnappinger; R Liao; M I Harrell; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

7.  Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific.

Authors:  Christian Fritz; Silvia Maass; Andreas Kreft; Franz-Christoph Bange
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 8.  The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy.

Authors:  T Szekeres; M Fritzer-Szekeres; H L Elford
Journal:  Crit Rev Clin Lab Sci       Date:  1997       Impact factor: 6.250

9.  Oral immunization of swine with attenuated Salmonella typhimurium aroA SL3261 expressing a recombinant antigen of Mycoplasma hyopneumoniae (NrdF) primes the immune system for a NrdF specific secretory IgA response in the lungs.

Authors:  P K Fagan; M J Walker; J Chin; G J Eamens; S P Djordjevic
Journal:  Microb Pathog       Date:  2001-02       Impact factor: 3.738

10.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  24 in total

1.  Efficient growth inhibition of Bacillus anthracis by knocking out the ribonucleotide reductase tyrosyl radical.

Authors:  Eduard Torrents; Margareta Sahlin; Daniele Biglino; Astrid Gräslund; Britt-Marie Sjöberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-01       Impact factor: 11.205

2.  Staphylococcus aureus NrdH redoxin is a reductant of the class Ib ribonucleotide reductase.

Authors:  Inbal Rabinovitch; Michaela Yanku; Adva Yeheskel; Gerald Cohen; Ilya Borovok; Yair Aharonowitz
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

3.  The class Ib ribonucleotide reductase from Mycobacterium tuberculosis has two active R2F subunits.

Authors:  Marta Hammerstad; Asmund K Røhr; Niels H Andersen; Astrid Gräslund; Martin Högbom; K Kristoffer Andersson
Journal:  J Biol Inorg Chem       Date:  2014-03-02       Impact factor: 3.358

4.  Characterization of a Clp protease gene regulator and the reaeration response in Mycobacterium tuberculosis.

Authors:  Ashley M Sherrid; Tige R Rustad; Gerard A Cangelosi; David R Sherman
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

5.  Rapid construction of mycobacterial mutagenesis vectors using ligation-independent cloning.

Authors:  Ricardo Balhana; Neil G Stoker; Mahmudul Hasan Sikder; Francois-Xavier Chauviac; Sharon L Kendall
Journal:  J Microbiol Methods       Date:  2010-07-27       Impact factor: 2.363

6.  The phenolic glycolipid of Mycobacterium tuberculosis differentially modulates the early host cytokine response but does not in itself confer hypervirulence.

Authors:  Daniel Sinsimer; Gaelle Huet; Claudia Manca; Liana Tsenova; Mi-Sun Koo; Natalia Kurepina; Bavesh Kana; Barun Mathema; Salvatore A E Marras; Barry N Kreiswirth; Christophe Guilhot; Gilla Kaplan
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

7.  Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli.

Authors:  Helena I M Boshoff; Xia Xu; Kapil Tahlan; Cynthia S Dowd; Kevin Pethe; Luis R Camacho; Tae-Ho Park; Chang-Soo Yun; Dirk Schnappinger; Sabine Ehrt; Kerstin J Williams; Clifton E Barry
Journal:  J Biol Chem       Date:  2008-05-19       Impact factor: 5.157

8.  NrdI essentiality for class Ib ribonucleotide reduction in Streptococcus pyogenes.

Authors:  Ignasi Roca; Eduard Torrents; Margareta Sahlin; Isidre Gibert; Britt-Marie Sjöberg
Journal:  J Bacteriol       Date:  2008-05-23       Impact factor: 3.490

9.  Gallium nitrate is efficacious in murine models of tuberculosis and inhibits key bacterial Fe-dependent enzymes.

Authors:  Oyebode Olakanmi; Banurekha Kesavalu; Rajamouli Pasula; Maher Y Abdalla; Larry S Schlesinger; Bradley E Britigan
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

10.  An anaerobic-type alpha-ketoglutarate ferredoxin oxidoreductase completes the oxidative tricarboxylic acid cycle of Mycobacterium tuberculosis.

Authors:  Anthony D Baughn; Scott J Garforth; Catherine Vilchèze; William R Jacobs
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.